Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.805 USD | -1.93% | -1.17% | -59.13% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 328M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -55M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.92
x | P/E ratio 2025 * |
-5.75
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | -1.93% | ||
1 week | -1.17% | ||
Current month | +4.25% | ||
1 month | -11.31% | ||
3 months | -38.03% | ||
6 months | -33.71% | ||
Current year | -59.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 3.805 | -1.93% | 452 092 |
24-05-09 | 3.88 | +4.58% | 1,001,710 |
24-05-08 | 3.71 | -3.39% | 1,010,038 |
24-05-07 | 3.84 | 0.00% | 876,789 |
24-05-06 | 3.84 | -0.26% | 673,073 |
Delayed Quote Nasdaq, May 10, 2024 at 01:24 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.13% | 328M | |
+3.19% | 108B | |
+11.12% | 104B | |
+1.28% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.72% | 17.64B | |
+4.19% | 14.05B | |
+34.65% | 12.51B |
- Stock Market
- Equities
- AVXL Stock